IVMatters

Some newly issued guidance regarding Optical Imaging from the Food and Drug Administration. https://lnkd.in/emyNzjpB Sets forth practical recommendations for clinical trial design which should bode well for the Optical Imaging Agent, drug component development. It provides for an “Intrasubject Control Design” to get surgeons on board early and a “Parallel-Arm Control Design” to align all stakeholders. It is interesting to see references made to the successful radiotracer 99Tc tilmanocept for sentinel lymph node mapping in the context of developing optical imaging agents. Some other noteworthy points of clarity in the guidance include the delineation of anatomical structures and intraoperative fluorescence angiography. #FDA FDA #radiology #surgery #opticalimaging #contrastmedia #imagingagent #fluoresence #

Thank you FLOTUS and the White House Initiative on Women’s Health Research for recommending urgent improvements in care for women’s health in America and for specifically mentioning the need to address #osteoporosis. Assuring better post-fracture care for the nearly 2 million women and men who suffer fractures every year will save taxpayers $ and save lives. https://lnkd.in/erBFM2m2

On behalf of and IVMatters, we thank the International Society for Clinical Densitometry and its participating clinicians for conducting a wonderful R.T. educational venue this past weekend. As a technical marketer and developer of medical devices, I find listening to clinicians at these venues most enjoyable, enlightening, and informative. Thank you for sharing content on: Diagnosis of Osteoporosis Pediatric DXA from A-Z Review of DXA/Understanding complex scans (Hard DXA Cases) Introduction to Vertebral Fracture Assessment Why and How of Precision Cross Calibration 2023 ISCD Official Positions Basics of Hologic Basics of GE Lunar Looking forward to the April clinical venue. American Society of Radiologic Technologists, Echolight #osteoporosis #bonehealth #REMS

Echolight looks forward to supporting its U.S. commercialization partner JUVENT at the Health and Freedom Summit in downtown Atlanta today through Sunday. https://lnkd.in/enu2cvEr Please stop by the JUVENT Health exhibit to learn how Echolight REMS can support your patient's musculoskeletal health and wellness. Echolight's ECHOs is an FDA-approved bone densitometry platform based on Radiofrequency Echographic Multi-Spectrometry (REMS) ultrasound. ECHOS is a mobile point-of-care platform providing bone densitometry, fracture risk, and body composition diagnostic reporting for your practice.   #integratedmedicine #musculoskeletalhealth #osteoporosis #Atlanta #wellness #bonehealth #REMS Juvent IVMatters Echolight

Echolight looks forward to supporting its U.S. commercialization partner JUVENT Health at the International College of Integrative Medicine 2024 Inflammaging Conference starting this Thursday. Echolight's ECHOs is an FDA-approved bone densitometry platform based on Radiofrequency Echographic Multi-Spectrometry (REMS) ultrasound. ECHOS is a mobile point-of-care platform providing bone densitometry, fracture risk, and body composition diagnostic reporting for your practice.   Please stop by the JUVENT Health exhibit to learn how Echolight REMS can support your patient's musculoskeletal health and wellness.   International College of Integrative Medicine #integratedmedicine #musculoskeletalhealth #osteoporosis #NewOrleans #bonehealth Juvent Echolight IVMatters

An interesting paper out of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota. https://bit.ly/3SsHbap The authors conclude that; “A minority of patients with cirrhosis are screened for osteoporosis despite higher rates of abnormal bone density compared to the general population.” Their conclusions are based on a retrospective review of patient histories in a single health system for patients diagnosed with cirrhosis. As a lay reader, a disproportionate mismatch between the prevalence of cirrhosis related osteoporosis and diagnostic bone mineral density testing is evident. It is highlighted that the lack of bone mineral density diagnostics in cirrhosis patients can be attributed to multiple U.S. society guidelines that do not site cirrhosis as a risk factor to necessitate osteoporosis screening. Similarly, primary care providers' awareness of cirrhosis as an osteoporosis risk factor to warrant recommending screening may be low. Additionally, patient compliance for those patients in this population recommended osteoporosis screening appears sub-optimal. Echolight REMS provides an easy-to-use point-of-care ultrasound solution for osteoporosis screening. www.echolightmedical.com Please get in touch with us to learn how we can help you provide REMS bone diagnostics to your patients. #osteoporosis #BMD Echolight IVMatters #hepatology #liverdisease #cirrhosis #nash #gastroenterology #universityofminnesota